Article Sidebar
Views PDF: 7
STUDY ON TP53 GENE MUTATION STATUS BY IMMUNOHISTOCHEMISTRY AND ITS RELATIONSHIP WITH HISTOPATHOLOGICAL CHARACTERISTICS OF BREAST CARCINOMA
Main Article Content
Abstract
Abstract:
(1) Objective: The TP53 gene mutation status is related to prognosis and treatment response in breast cancer. Immunohistochemistry with the p53 marker is used as an alternative method to analyze TP53 mutations. The study aimed to evaluate TP53 gene status by immunohistochemistry and its association with histopathological features of breast carcinoma. (2) Method: Cross-sectional description, purposive sampling of 50 patients with a pathological diagnosis of invasive breast carcinoma at Military Hospital 103 from May 2022 to May 2023. (3) Results: TP53 mutations account for 70% of invasive breast carcinoma. The TP53 mutation rate increased as the NPI prognostic index increased (p < 0.05). Patients with ER negative, PR negative, high Ki67 index, and HER2/neu protein overexpression have a higher TP53 mutation rate than others (p < 0.05). TP53 mutations were found in triple-negative patients and the HER2 group was higher than in the luminal group (p < 0.05). (4) Conclusion: TP53 gene mutation status can be determined by immunohistochemical phenotype in invasive breast carcinoma. Among histopathological features, it is associated with NPI prognostic index, ER, PR and HER2 expression, Ki67 proliferation index, and molecular subtype of breast carcinoma.
Article Details
Keywords
Breast carcinoma, TP53 gene mutation, immunohistochemistry
References
2. Kern R, Correa SC, Scandolara TB, Carla da Silva J, Pires BR, Panis C. Current advances in the diagnosis and personalized treatment of breast cancer: Lessons from tumor biology. Personalized Medicine. 2020; 17(05): 399-420.
3. Donehower LA, Soussi T, Korkut A, et al. Integrated analysis of TP53 gene and pathway alterations in the cancer genome atlas. Cell reports. Jul 30 2019; 28(5):1370-1384.e5. DOI:10.1016/j.celrep.2019.07.001
4. Bertheau P, et al. P53 in breast cancer subtypes and new insights into response to chemotherapy. The Breast. 2013; 22:27-29.
5. Köbel M, Ronnett BM, Singh N, Soslow RA, Gilks CB, McCluggage WG. Interpretation of P53 immunohistochemistry in endometrial carcinomas: Toward increased reproducibility. International Journal of Gynecological Pathology: Official journal of the International Society of Gynecological Pathologists. Jan 2019; 38(1):123-131. DOI:10.1097/pgp. 0000000000000488.
6. Murnyák B, Hortobágyi T. Immunohistochemical correlates of TP53 somatic mutations in cancer. Oncotarget. Oct 4 2016; 7(40):64910-64920. DOI:10.18632/oncotarget.11912
7. Nguyễn Văn Chủ, Nguyễn Quang Tiến, Vũ Thị Ngọc Hà, Phùng Thị Huyền, Phạm Khoa Hồng, Lê Đình Roanh. Combined p53 and Bcl2 immunophenotypes in prognosis of Vietnamese invasive breast carcinoma: A single institutional retrospective analysis. Technology in Cancer Research & Treatment. 2020; 19:1-12.
8. Sirvent J, et al. P53 in breast cancer. Its relation to histological grade lymph node status hormone receptors cell proliferation fraction ki67 and cerbB2. Immunohistochemical study of 153 cases. Histology and Histopathology. 1995; 10:531-539.
9. Dumay A, Feugeas JP, Wittmer E, et al. Distinct tumor protein p53 mutants in breast cancer subgroups. International journal of cancer. Mar 1, 2013; 132(5):1227-1231. DOI:10.1002/ ijc.27767
10. Desmedt C, Voet T, Sotiriou C, Campbell PJ. Next-generation sequencing in breast cancer: First take home messages. Current Opinion in Oncology. 2012; 24:597-604.
11. Yang P, et al. The impact of p53 in predicting clinical outcome of breast cancer patients with visceral metastasis. Scientific Reports. 2013; 3(1):1-6.
12. Hashmi AA, Sajid A, Hussain M, et al. Mutant phenotype p53 immunohistochemical expression Is associated with poor prognostic parameters and disease-free survival in triple-negative metaplastic breast carcinoma. Cureus. 2021; 13(5): e15244.